[Biomarkers in cardio-oncology patients]

Area of Science:

• Cardio-oncology
• Biomarker discovery
• Cancer therapeutics

Background:

• Cancer treatments have improved survival rates, but cardiotoxicity is a growing concern.
• Cardiotoxicity encompasses a range of cardiovascular side effects, including heart failure and arrhythmias.
• Evaluating cardiotoxicity, especially with newer therapies, remains a diagnostic challenge.

Purpose of the Study:

• To review current knowledge on biomarkers for detecting cancer therapy-induced cardiotoxicity.
• To outline potential clinical recommendations for biomarker-based cardiotoxicity screening.
• To highlight the role of cardiac biomarkers in managing patients undergoing cancer treatment.

Main Methods:

• Literature review of studies on cardiac biomarkers in cancer patients.
• Analysis of troponin and natriuretic peptide roles in cardiotoxicity detection.
• Evaluation of biomarker utility in various cardiotoxic syndromes and therapies.

Main Results:

• Elevated troponin and natriuretic peptides (BNP/NT-proBNP) correlate with increased mortality and heart failure risk.
• Troponin aids in identifying myocarditis linked to immune checkpoint inhibitors.
• Biomarkers show promise in early detection and monitoring of cardiotoxicity.

Conclusions:

• Cardiac biomarkers are vital tools in the field of cardio-oncology.
• Biomarker monitoring can aid in the early detection and management of cardiotoxicity.
• Further research and clinical guidelines are needed to optimize biomarker use in cancer patients.